busi fire cylind bullish thesi intact
remain overweight rate share follow nice updat top-
bottom-lin beat put take across product franchis importantli humira
skyrizi beat outlook abbv stand-alone guidanc notabl ex-
us humira revenu stabil signific upsid expect on-going skyrizi
rinvoq launch though wait deal close later month
combin compani guidanc focu shift label expans growth product
number clinic proof-of-concept updat expect pipelin year
continu like setup name incorpor today updat guidanc
price target goe remain buyer
beat report top- bottom-lin beat non-gaap ep
consensu psc total revenu consensu
psc put take quarter upsid driven
perform immunolog heme-onc portfolio includ humira
consensu psc imbruvica beat consensu
psc partial off-set hcv franchis miss
combin compani guidanc still come stand-alone guidanc impress
acquisit close quarter well get combin compani guidanc
time provid stand-alone guidanc includ
adjust ep consensu oper revenu
growth impli revenu consensu skyrizi
continu launch strength sale guid well consensu
estim psc rinvoq sale shi consensu
quarter manag note market access inflect occur januari
paid prescript ramp given rinvoq revenu guid
consensu though somewhat shi estim psc
survey work indic robust uptak derm rheum
above-consensu skyrizi/rinvoq guidanc come surpris
label expans expect number catalyst tap signific amount
time call today focus growth product skyrizi rinvoq venclexta
orilissa expect label expans includ move ad skyrizi rinvoq
data anticip rinvoq earli stage pipelin
tnf steroid conjug highlight today poc data ra expect
year note five addit poc readout expect continu
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
ep discount back
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
remain buyer allergan acquisit close soon skyrizi rinvoq drive
upsid continu like setup part shift impact agn
acquisit revis estim incorpor today extens
product guidanc updat price target increas higher ep
partial laps discount period remain buyer
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www pipersandl com/researchdisclosur
page
dollar except per share data
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit shaqe
current disclosur inform compani locat http //www pipersandl com/researchdisclosur
